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Abstract
Most cancer deaths are due to metastases. Markers of epithelial-mesenchymal transition (EMT) 
measured in primary tumor cancer cells could be helpful to assess patient risk of metastatic 
disease, even among those otherwise diagnosed with local disease. Previous studies of EMT 
markers and patient outcomes used inconsistent methods and did not compare the clinical impact 
of different expression cut points for the same marker. Using digital image analysis, we measured 
the EMT markers Snail and E-cadherin in primary tumor specimens from 190 subjects in tissue 
microarrays from a population-based prospective cohort of colorectal cancer patients and 
estimated their associations with time-to-death. After measuring continuous marker expression 
data, we performed a systematic search for the cut point for each marker with the best model fit 
between dichotomous marker expression and time-to-death. We also assessed the potential clinical 
impact of different cut points for the same marker. After dichotomizing expression status at the 
statistically-optimal cut point, we found that Snail expression was not associated with time-to-
Robert S. Sandler, rsandler@med.unc.edu. 
Electronic supplementary material The online version of this article (doi:10.1007/s10585-015-9757-7) contains supplementary 
material, which is available to authorized users.
Compliance with ethical standards
Conflicts of interest The authors have no conflicts of interest to report.
Human and animal rights and informed consent All procedures performed in studies involving human participants were in 
accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration 
and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in 
the study.
HHS Public Access
Author manuscript
Clin Exp Metastasis. Author manuscript; available in PMC 2017 January 01.
Published in final edited form as:
Clin Exp Metastasis. 2016 January ; 33(1): 53–62. doi:10.1007/s10585-015-9757-7.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
death. When measured as a weighted average of tumor cores, low E-cadherin expression was 
associated with a greater risk of dying within 5 years of surgery than high expression (risk 
difference = 33 %, 95 % confidence interval 3–62 %). Identifying a clinically-optimal cut point for 
an EMT marker requires trade-offs between strength and precision of the association with patient 
outcomes, as well as consideration of the number of patients whose treatments might change based 
on using the marker at a given cut point.
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Introduction
Roughly 90 % of cancer deaths are due to metastases [1]. Current methods to assess 
metastatic disease at diagnosis—examination of regional lymph nodes and radiologic 
imaging—do not always successfully detect metastases that are present, leading to false 
diagnoses of local disease. For example, approximately 25 % of colorectal cancer (CRC) 
patients diagnosed with local disease later experience recurrence [2]. Markers of epithelial-
mesenchymal transition (EMT) [3–5] measured in primary tumor cancer cells could provide 
an additional test of risk for metastatic disease to guide treatment decisions, even when 
metastases are not detected by the two standard tests.
EMT is a mechanism of cancer cell metastasis that involves epithelial cells temporarily 
becoming mesenchymal cells [4]. This occurs when cellular expression levels of EMT 
inducers increase, triggering decreased expression of epithelial markers and increased 
expression of mesenchymal markers. These changes lead to loss of adhesion to adjacent 
cells—enabling detachment of the transitioning cell from the primary tumor—as well as 
modifications that enhance motility and invasiveness.
Past studies of associations between EMT markers in primary tumors and patient outcomes 
have measured and analyzed marker expression data using inconsistent methods [6]. For 
instance, different studies of the same marker measured using the same laboratory technique 
have often used different scoring scales and defined high versus low expression differently. 
Ordinal marker expression data have frequently been collected, limiting the ability to 
identify clinically useful cut points to define marker expression status. The lack of uniform, 
clinically-informative methods across studies could contribute to inconsistent findings and 
hamper translation of EMT markers to clinical use.
To facilitate translation of EMT markers, we developed new approaches that permit direct 
evaluation of how an EMT marker could be implemented clinically. We focused on digital 
image analysis of immunostained tissue specimens to obtain continuous marker expression 
data, statistical evaluation of the clinical utility of a given cut point to define high versus low 
marker expression, and rigorous selection of covariates to include in multivariate models.
To illustrate our approach, we measured the EMT inducer Snail and epithelial marker E-
cadherin in primary tumors from a population-based prospective cohort study of CRC 
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mortality and estimated their associations with time-to-death. We hypothesized that low 
expression of E-cadherin and high expression of Snail would be associated with shorter 
times from surgery to death compared to opposite expression levels.
Materials and methods
Study population
Subjects were enrolled in the Cancer Care Outcomes Research and Surveillance Consortium 
(CanCORS), a population-based, prospective, case-only, multi-site observational study of 
colorectal and lung cancer patients [7]. Briefly, the study assessed the impact of health-
system, provider, and patient factors on cancer outcomes. Patients were at least 21 years of 
age at diagnosis and were enrolled within 3 months of diagnosis during 2003–2006. The 
study collected patient surveys, surrogate surveys for patients who were deceased or too ill 
to participate, and medical records data [8]. Vital status for all subjects was verified using 
the Social Security Death Index on 4 May 2010, providing at least 42 months of follow-up 
observation per individual.
The North Carolina CanCORS site enrolled 990 CRC patients and was the only one to 
collect tumor specimens. Subjects in the present biomarker study came from a catchment 
area of 33 counties in eastern and central North Carolina at the time of diagnosis. 
Investigators obtained primary tumor and non-neoplastic adjacent colorectal tissue samples 
from 506 subjects.
Formalin-fixed, paraffin-embedded tissue specimens were sent from hospitals across the 
catchment area to the University of North Carolina at Chapel Hill (UNC), where they were 
used to construct tissue microarrays (TMAs) as described previously [9]. Most subjects had 
multiple cores from both primary tumor and “normal” (non-neoplastic) margin. We 
measured EMT markers in 12 representative TMAs that included specimens from 219 
subjects. To be included in the study sample, subjects had to have at least one core of tumor 
tissue successfully stained for one marker, with that core having at least 50 epithelial cells 
and unambiguous histology. From the 12 TMAs, we excluded 26 subjects lacking adequate 
tumor tissue and an additional 3 subjects who could not be linked to medical records data, 
yielding a final study sample of 190 subjects.
Immunohistochemistry
We selected EMT markers for evaluation based on the results of previous studies and 
criteria discussed in our prior literature review [6]. Marker protein expression was measured 
using the following antibodies: E-cadherin [mouse monoclonal ready to use (RTU), clone 
36B5 (cat #PA0387) from Leica Microsystems Inc. (Norwell, MA)] and Snail [goat 
polyclonal (ab53519) from Abcam (Cambridge, MA)].
Immunohistochemistry (IHC) was performed at the UNC Translational Pathology 
Laboratory (TPL) using the Bond fully-automated slide staining system (Leica 
Microsystems Inc., Norwell, MA). Slides were deparaffinized in Bond Dewax solution 
(AR9222) and hydrated in Bond Wash solution (AR9590). Antigen retrieval was performed 
at 100 °C for Snail (for 30 min) in Bond-epitope retrieval solution 1 at pH 6.0 (AR9961) and 
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for E-cadherin for 20 min at 100 °C in solution 2 at pH 9.0 (AR9640). After pretreatment, 
anti-E-cadherin was applied for 15 min and anti-Snail (1:200) for 30 min.
Detection of Snail was performed using the Bond Intense R Detection System (DS9263) 
supplemented with the LSAB + kit (DAKO, Carpinteria, CA). E-cadherin detection used the 
Bond Polymer Refine Detection System (DS9800). Stained slides were dehydrated and 
cover-slipped. Positive and negative controls (no primary antibody) were included for each 
antibody. All assays were single-marker (i.e., no multiplex assays).
To verify E-cadherin antibody specificity, tonsil tissue was stained both with and without 
primary antibody (positive and negative controls, respectively). Snail antibody specificity 
was confirmed in normal kidney (positive control) and normal liver (negative control) [10, 
11]. Additional negative controls were performed with goat IgG (Santa Cruz, sc-2755) used 
in place of the Snail antibody. Both antibodies stained appropriately in the relevant sub-
cellular compartments (E-cadherin, plasma membrane; Snail, nucleus) in each tissue (see 
Online Resource 3, Figs. S1 and S2).
Stained slides were digitally imaged at ×20 magnification using the Aperio ScanScope XT 
(Aperio Technologies, Vista, CA). Digital images were stored in the Aperio Spectrum 
Database.
Example images of staining for colorectal tissue from CanCORS subjects are provided in 
Online Resource 3 (Fig. S3).
Automated analysis of digital IHC images
Computer algorithms annotated and scored every eligible tissue core to obtain continuous 
marker expression data. We used approximately 65 cores originating from two TMAs for 
algorithm training and automated-analysis validation.
Definiens Composer Technology (Tissue Studio version 2.1.1 with Tissue Studio Library 
version 3.6.1; Definiens Inc., Carlsbad, CA) was used to annotate images for regions 
enriched in epithelial cells in IHC-stained TMA cores. To detect differences in cell shape 
and tissue structure, we developed two Composer algorithms per marker—for non-
neoplastic adjacent and tumor tissue, respectively—as both types of tissue were present on 
each TMA.
We then developed two Tissue Studio scoring algorithms (“solutions”) per marker (non-
neoplastic and tumor tissue). E-cadherin membrane and cytoplasmic staining were measured 
on a continuous average intensity scale of 0–3. Snail was measured as core percent positive 
nuclei on a continuous scale of 0–100. Several additional Snail scoring algorithms were 
developed, but only scores based on the first algorithm were used for modeling (see Online 
Resource 1 for further details).
To evaluate the reliability of computer annotations, one of us (ELB) used Aperio 
ImageScope (version 11.2; Leica Biosystem, Buffalo Grove, IL) to manually annotate the 
same 65 cores per marker that were used to optimize Tissue Studio solutions. He remained 
blind to patient and tumor characteristics while annotating. Automated scores obtained via 
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manual and automated annotation produced Pearson correlations of 0.91 for E-cadherin and 
0.94 for Snail. All 12 TMAs stained for E-cadherin and Snail were then analyzed (24 slides 
in total).
Subjects typically had multiple cores available of a given tissue type (tumor or non-
neoplastic). To assign an expression value for each subject by marker and tissue type, we 
handled replicate cores in two ways: first, as a weighted average of cores, and second, by 
assigning the expression value of the subject's “worst core” as the marker expression value. 
For weighted averages, the weights were area analyzed for E-cadherin and number of nuclei 
for Snail. The worst core by tissue type was assigned as the lowest core average intensity for 
E-cadherin and as the highest core percent positive nuclei for Snail.
See Online Resource 1 for further details on algorithm development and validation. See 
Online Resource 3 for example images of annotations and scoring in colorectal tumor and 
non-neoplastic tissue (Figs. S4, S5).
Outcome
In statistical models, the dependent variable was length of time in days from primary tumor 
surgery until all-cause mortality, with administrative censoring at 5 years after surgery.
Covariates
Covariates for multivariate statistical models were selected based on prior studies [6], 
considerations of biological plausibility, and directed acyclic graph theory [12].
Per directed acyclic graph theory, we adjusted for those variables considered to be common 
causes of both the independent variable of interest (EMT marker expression in primary 
tumor cancer cells) and the dependent variable (time from surgery to death): age, 
neoadjuvant chemotherapy, neoadjuvant radiation therapy, tumor size (T-stage), lymph-node 
metastasis diagnosis (N-stage), and distant-metastasis diagnosis (M-stage). We used overall 
TNM stage as a single covariate instead of adjusting for the component stages as three 
separate variables since including both overall stage and any of the component stages would 
constitute inappropriate overadjustment.
Pre-surgery treatments consisted of neoadjuvant chemotherapy and neoadjuvant radiation 
therapy as two separate variables, each coded as received or not received. Cancer treatments 
(chemotherapy and radiation therapy) prior to surgery were included as covariates but 
treatments administered after surgery were not included. While treatments at either time are 
related to time-to-death, the observed EMT marker expression in primary tumor cancer cells 
could only have been exposed to treatments before surgery because the primary tumor 
remained in the body at that point, whereas the tumor was removed before the 
administration of post-surgery treatments. Based on directed acyclic graph theory, we 
concluded that other variables related to CRC prognosis—such as microsatellite status, 
tumor budding, and KRAS status—should not be adjusted for in multivariate models.
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Identification of statistically-optimal marker expression cut point
For each continuous marker expression variable, we identified the cut point distinguishing 
high expression from low expression that was most strongly associated with time-to-death.
For every possible cut point along any marker expression continuum, we defined high 
expression as expression at or above the cut point and low expression as expression below 
the cut point. Whether high expression is clinically desirable depends on the particular 
marker. High E-cadherin status would be expected to correlate with better outcomes (i.e., 
longer time-to-death) [4, 6, 13], whereas high Snail [4, 6] status would be expected to 
correlate with worse outcomes.
To identify the statistically-optimal cut point for each continuous marker expression 
variable, we iteratively dichotomized marker expression at every possible cut point in the 
observed tumor tissue data, with each cut point corresponding to a different subject's 
expression value. Each dichotomization of marker expression status was fit as the only 
independent variable in a Cox proportional hazards model with time-to-death as the 
outcome, producing a model fit statistic. The cut point with the lowest model fit statistic was 
considered statistically optimal.
For macro SAS code and further details, see Online Resource 2.
Statistical analysis
The data collection yielded four continuous marker expression variables: weighted average 
and worst core for each of the two markers. We first used unpaired two-sample t-tests to 
assess whether average continuous marker expression differed between tumor and non-
neoplastic tissue. All subsequent analyses used tumor tissue only. We applied the macro to 
the tumor tissue data for the four continuous marker expression variables to identify the 
statistically-optimal cut point for each. Every optimal cut point was used to create a 
dichotomous marker expression variable (low versus high for E-cadherin, high versus low 
for Snail).
We generated Kaplan–Meier survival curves stratified by dichotomous marker expression 
status for one marker or two markers jointly, assessing differences between strata using the 
logrank test. Next, for each optimally-dichotomous marker expression variable, we fit 
unadjusted and adjusted Cox proportional hazards models of time-to-death. For marker 
expression variables found to be associated with patient outcomes at their statistically-
optimal cut points, we evaluated additional cut points to explore whether the statistically-
optimal cut point ought to be considered the clinically-optimal cut point.
Prior to modeling, non-informative observations (e.g. “No Answer,” “Don't Know,” 
“Unknown”) were recoded as missing. Missing data for all model variables were evaluated 
using multiple imputation. P values of 0.05 or below were considered statistically 
significant. All analyses were performed using SAS 9.3 (SAS Institute, Cary, NC). The 
Institutional Review Board at UNC approved the protocol. All subjects provided informed 
consent.
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Results
Subject characteristics are shown in Table 1. We found no differences between overall 
North Carolina CanCORS and the subset for whom EMT markers were measured in primary 
tumors.
On average, tumor tissue had lower E-cadherin expression than non-neoplastic adjacent 
tissue regardless of whether expression values were assigned as a weighted average of cores 
or as the worst core (Table 2). However, average Snail expression was higher in non-
neoplastic tissue than in tumor tissue (Table 2). While the difference was not large, this 
relationship was consistent across both ways of assigning expression values and all three 
Snail scoring algorithms (Table S1 in Online Resource 3).
On the average intensity scale of 0–3 for E-cadherin, we found that the statistically-optimal 
cut point was about 0.52 for weighted averages and 0.42 for worst cores. On a percent 
positive nuclei scale for Snail using the first nuclear scoring algorithm, the statistically-
optimal cut point was about 25.2 % for weighted averages and 63.6 % for worst cores. For 
each marker expression variable, Table 3 presents the number of subjects by statistically-
optimal dichotomous marker expression status.
For E-cadherin weighted averages, subjects with low tumor expression had worse survival 
than those with high tumor expression (Fig. 1). None of the Kaplan–Meier curves stratified 
by the other three optimally-dichotomous marker expression variables revealed a 
statistically-significant difference in survival (not shown). A survival curve jointly stratified 
by E-cadherin and Snail weighted average status had a significant logrank test (see Online 
Resource 3, Fig. S6). Among the strata of joint expression status, no pattern consistent with 
the study hypotheses was observed.
Unadjusted and adjusted proportional hazards model results paralleled the single-variable 
stratified survival curves. Low E-cadherin weighted average expression was associated with 
greater hazards of dying than high expression both when unadjusted [Hazard ratio (HR) = 
2.84, 95 % Confidence Interval (CI) 1.29–6.28] and adjusted (HR = 2.57, 95 % CI 1.10–
6.03), while no associations were found for any of the other optimally-dichotomous 
expression variables (Table 4).
To evaluate whether the statistically-optimal cut point would be clinically optimal, we 
explored several trade-offs between strength of cut-point/time-to-death association and the 
number of subjects whose treatments might change due to clinical use of EMT markers. 
Specifically, we considered three different E-cadherin weighted average cut points that were 
either statistically significant or nearly so: about 0.52 (statistically-optimal value), 0.60, and 
0.85 (Table 5). Setting the cut point to a value other than the statistically-optimal value led 
to hazard ratio point estimates that were weaker than the one at the optimal cut point, but 
marker expression status was still effectively associated with outcomes at each of these cut 
points. Notably, the precision of hazard ratio estimates was better at cut points other than the 
statistically-optimal value, with a confidence limit ratio of 5.48 at a cut point of 0.52, 3.48 at 
a cut point of 0.60, and 3.11 at a cut point of 0.85.
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The number of subjects whose treatments might change based on E-cadherin measurements
—those diagnosed with local disease but who had low E-cadherin expression—varied 
substantially with cut point. Of 99 subjects with E-cadherin measurements and diagnosed 
with local disease, 6 had low expression at the statistically-optimal cut point, 16 at a cut 
point of 0.60, and 56 at a cut point of 0.85 (Table 5).
Discussion
EMT markers measured in primary tumor cancer cells could potentially improve the 
accuracy of cancer staging by identifying patients at risk for metastatic disease who have 
false negative test results for both lymph node evaluation and radiologic imaging. This 
improvement in staging could lead to more appropriate treatment decisions that would 
reduce the number of patients diagnosed with local disease who later experience recurrence, 
ultimately improving survival outcomes.
Successful translation requires consistent, clinically-informative design of studies of EMT 
markers and patient outcomes. Although marker expression is naturally continuous, the 
clinical purpose of the markers is to guide therapy. Since treatment decisions are inherently 
binary, what matters is dichotomous marker expression. Therefore, the choice of cut point to 
dichotomize continuous marker expression is critical.
We developed approaches to EMT marker measurement and analysis that allow evaluation 
of the clinical utility of an EMT marker at different cut points. As a proof of principle, we 
measured two EMT markers in a set of CRC primary tumors from a population-based 
prospective cohort study. We found that E-cadherin expression measured as a weighted 
average of tumor cores was associated with time to all-cause mortality independent of tumor 
stage, but Snail expression was not associated with outcomes. This implied that E-cadherin 
has promise as a marker to identify CRC patients at risk for metastatic disease independent 
of lymph node evaluation and imaging results.
Our results suggested that at least three criteria should be used to evaluate the association 
between dichotomous EMT marker expression at a given cut point and patient outcomes: 
strength of point estimate, precision, and the number of patients whose treatments would be 
changed by implementing the marker clinically at that cut point. Table 5 illustrates the 
information needed to compare the performance of an EMT marker at different cut points.
The table shows that, while multiple E-cadherin cut points were associated with time to all-
cause mortality, there were trade-offs between them in terms of clinical performance. On a 
continuous average intensity scale of 0–3, the statistically-optimal cut point (in terms of 
model fit) of 0.52 had the strongest point estimate in terms of being furthest from the null 
value. A cut point of 0.85 had the best precision.
In terms of the patients whose treatments would change by implementing E-cadherin as a 
diagnostic tool, this would consist of those diagnosed with local disease according to lymph 
node evaluation and imaging but who had low E-cadherin expression. Without knowledge of 
E-cadherin status, these patients would not generally receive adjuvant chemotherapy [14], 
but after introducing the marker, they might be considered for chemotherapy. Recall that 
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about 25 % of CRC patients diagnosed with local disease later experience recurrence [2]. 
This suggests that a useful cut point for E-cadherin in CRC would yield an approximate 
distribution of 25 % low expression and 75 % high expression among those diagnosed with 
local disease according to lymph node evaluation and imaging. Our study had 99 subjects 
with E-cadherin measurements who were diagnosed with local disease. The recurrence data 
for CRC patients diagnosed with local disease implies that an effective cut point would yield 
a distribution of about 25 low E-cadherin and 74 high E-cadherin expression status among 
these 99 subjects. Of the three cut points in Table 5, a cut point of 0.60 came closest to this 
distribution.
Our approach had several important strengths. First, digital image analysis yielding 
continuous marker expression data maximized the opportunity to identify the most clinically 
useful cut point [15]. In contrast, collecting dichotomous or ordinal marker data, such as are 
obtained by manual IHC scoring, would obscure much of the natural variation that may be 
present and greatly reduces the number of cut points that can be explored. Second, our 
approach to analyzing the data permitted direct evaluation of the clinical impact of using a 
particular marker at a given cut point. It also allowed straightforward comparison of the 
strengths and weaknesses of different cut points for the same marker in the same study 
sample. Choosing cut points based on biologically arbitrary criteria such as percentiles of 
marker expression is not recommended [16].
Third, the selection of covariates for multivariate models has varied considerably and been 
without justification in previous studies [6]. Our approach was to identify a wide range of 
possibilities using prior literature and then determine whether to include or exclude each 
possibility based on directed acyclic graph theory [12]. Finally, our sample was population-
based, implying that our results could have greater generalizability than the hospital-based 
samples that have dominated prior studies [6, 17]. Although the subjects in this analysis 
were approximately 20 % of those enrolled in North Carolina CanCORS, we found no 
differences in subject characteristics between overall North Carolina CanCORS and those 
included in the EMT study sample (Table 1). This suggested that the EMT study sample 
remained representative of the underlying source population.
In terms of limitations, first, the only available outcome was time from surgery to all-cause 
mortality. It would have been informative to also examine associations between marker 
expression and time to cancer-specific mortality as well as time to recurrence, but these 
alternative outcomes were not measured in CanCORS. Second, the sample size was small, 
which prevented division of the subjects into separate training and validation sets with 
sufficient power to detect an association between marker expression and outcomes.
Finally, our study did not sample tumors in a consistent way. Ideally, every tumor would 
have been sampled at each of the invasive front, tumor center, and an edge of the tumor 
away from the invasive front [6]. However, for any given tumor in our dataset, we did not 
know from which part of the tumor our tissue specimens came. EMT marker expression 
could vary throughout a tumor and it may be that, for clinical purposes, physicians should 
always sample a particular portion (e.g. the invasive front). Had systematic tumor sampling 
been performed, we could have calculated portion-specific estimates of, say, the association 
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between invasive front E-cadherin and time-to-death, and separately, the association 
between tumor center E-cadherin and time-to-death. Unfortunately, we could not analyze the 
data this way given the random tumor sampling.
An important implication of this study for clinical cancer pathology is that EMT marker 
immunohistochemical measurements should be incorporated into clinical practice using 
digital image analysis to obtain a continuous expression score on a scale standardized for the 
particular marker. This score should then be compared to a cut point specific to the marker 
that has been identified via epidemiologic studies and is based on a consideration of the 
criteria discussed above: strength of association with patient outcomes, precision of 
association, and proportion of patients diagnosed with local disease according to lymph node 
evaluation and radiologic imaging whose treatments would change based on EMT marker 
status. For CRC, our results suggest that a finding of low E-cadherin levels could signal to 
clinicians that cancer cells were likely detaching from the primary tumor prior to surgery.
This study furthers translational EMT research in both specific and general ways. 
Specifically, our results imply that E-cadherin is a promising marker to identify CRC 
patients at risk for metastatic disease even when metastases are not detected by lymph node 
evaluation and imaging. More generally, we have developed an approach to measurement 
and analysis of EMT marker data that is more rigorous, thorough, and clinically-informative 
than techniques described in previous studies. This approach is not specific to CRC and 
could benefit future studies in different tumor sites. Adoption of our approach could 
facilitate translation of EMT markers to clinical use and thereby improve outcomes across a 
wide spectrum of cancer patients.
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Fig. 1. 
Kaplan-Meier overall survival stratified by expression status of E-cadherin measured as a 
continuous weighted average of tumor cores and then dichotomized at the statistically-
optimal cut point (E+ = high expression, E− = low expression)
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Table 1
Subject characteristics for overall North Carolina CanCORS and subset in whose primary tumors EMT 
markers were measured
Characteristic mean (SD) or N (%)a Overall NC-CanCORS EMT study sample P value
(N = 990) (N = 190)
Age at baseline (years) 66.3 13.2 66.6 13.1 0.8
Sex 0.6
    Male 488 49.3 % 90 47.4 %
    Female 502 50.7 % 100 52.6 %
Race 0.6
    Non-hispanic white 762 77.0 % 150 78.9 %
    Other 228 23.0 % 40 21.1 %
Tumor stage 0.9
    Local 437 51.1 % 100 52.6 %
    Regional 311 36.4 % 66 34.7 %
    Distant 107 12.5 % 24 12.6 %
    Missing/noninformative 135 0
Tumor location 0.07
    Proximal 279 42.9 % 82 50.9 %
    Distal 371 57.1 % 79 49.1 %
    Missing/noninformative 340 29
Tumor grade 0.4
    Well/moderately differentiated 539 83.7 % 129 81.1 %
    Poorly/not differentiated 105 16.3 % 30 18.9 %
    Missing/noninformative 346 31
Neoadjuvant chemotherapy 0.3
    Yes 46 8.5 % 8 5.7 %
    No 496 91.5 % 132 94.3 %
    Missing/noninformative 448 50
Neoadjuvant radiation 0.09
    Yes 41 7.6 % 5 3.6 %
    No 501 92.4 % 135 96.4 %
    Missing/noninformative 448 50
Died within 5 years of baseline 366 37.0 % 62 32.6 % 0.3
a
Percentages are for informative non-missing data
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Table 3
Statistically-optimal dichotomous EMT marker expression status cross-tabulated with tumor stage and with 
risk of dying within 5 years of surgery
E-cadherin Snail
Weighted Averagea Worst Coreb Weighted Averagea Worst Coreb
Low High Low High Low High Low High
Stage
    Local 6 93 3 96 29 69 54 44
    Regional 5 61 3 63 14 51 45 20
    Distant 0 23 0 23 1 21 13 9
Mortality risk
    Died within 5 years (x) 7 55 3 59 17 44 43 18
    Total at risk (y) 11 177 6 182 44 141 112 73
    5-Year risk of death post-surgery (%) (x/y) 64 31 50 32 39 31 38 25
Of 190 overall subjects in the EMT study, the number with tumor tissue marker data available was 188 for E-cadherin and 185 for Snail Low 
expression status is expression in tumor tissue below the statistically-optimal cut point and high expression status is expression in tumor tissue at or 
above the statistically-optimal cut point. The a priori hypotheses were that low E-cadherin subjects would have worse outcomes while high Snail 
subjects would have worse outcomes. For the value of the statistically-optimal cut point for each marker expression variable, see “Materials and 
methods” section
a
Marker expression values assigned as weighted average of cores in tumor tissue (weighted by area analyzed for E-cadherin and number of nuclei 
for Snail)
b
Marker expression values assigned as expression in tumor tissue of the core with lowest expression for E-cadherin and highest expression for 
Snail
Clin Exp Metastasis. Author manuscript; available in PMC 2017 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Busch et al. Page 16
Table 4
Unadjusted and adjusted Cox proportional hazards models of the effect of optimally-dichotomized marker 
expression status on time-to-death censored at 5 years after surgery (n = 190)
Variable Weighted averagea Worst coreb
Unadjusted Adjustedc Unadjusted Adjustedc
HR 95 % CI HR 95 % CI HR 95 % CI HR 95 % CI
E-cadherind 2.84 1.29, 6.28 2.57 1.10, 6.03 1.53 0.47, 4.95 1.56 0.32, 7.63
Snaile 0.83 0.48, 1.45 0.61 0.33, 1.13 0.62 0.36, 1.08 0.57 0.32, 1.02
Prior to dichotomization, continuous E-cadherin measured as core average intensity (0–3) and continuous Snail measured as core percent positive 
nuclei (Snail) (0–100). Subjects with missing data for a given marker expression variable had values imputed to retain full sample size. For the 
value of the statistically-optimal cut point for each marker expression variable, see “Materials and methods” section
a
Marker expression values assigned as weighted average of tumor cores (weighted by area analyzed for E-cadherin and number of nuclei for Snail)
b
Marker expression values assigned as average intensity of the subject's tumor core with the lowest average intensity for E-cadherin, or as percent 
positive nuclei of the subject's tumor core with the highest percent positive nuclei for Snail
cAdjusted for age (continuous), TNM stage (local/regional/distant), neoadjuvant chemotherapy (yes/no), and neoadjuvant radiation therapy (yes/
no). Expression status for a given marker was not adjusted for the other markers
dComparison is low E-cadherin expression to high E-cadherin expression
eComparison is high Snail expression to low Snail expression
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Table 5
Trade-offs between strength and precision of cut-point/time-to-death association and number of patients with 
low or high expression, by stage distribution and 5-year risk of death, for multiple cut points of E-cadherin 
weighted average expression
Cut point 0.52b Cut point 0.60 Cut point 0.85
Cox model estimatea HR2.57
95 % CI (CLR)
1.10, 6.03 (5.48)
HR
2.40
95 % CI (CLR)
1.29, 4.49 (3.48)
HR
1.75
95 % CI (CLR)
0.99, 3.08 (3.11)
Stage Low High Low High Low High
    Local (n = 99) 6 93 16 83 56 43
    Regional (n = 66) 5 61 11 55 41 25
    Distant (n = 23) 0 23 1 22 11 12
Mortality risk
    Died within 5 years (n = 62) (x) 7 55 14 48 42 20
    Total at risk (n = 188) (y) 11 177 28 160 108 80
    5-year risk of death post-surgery (%) (x/y) 64 31 50 30 39 25
Mortality Risk Effect estimatesc Estimate 95 % CI Estimate 95 % CI Estimate 95 % CI
Risk difference (%) 33 3, 62 20 0, 40 14 1, 27
Risk ratio 2.05 1.25, 3.37 1.67 1.07, 2.59 1.56 0.99, 2.43
CLR Confidence limit ratio (upper limit/lower limit)
E-cadherin measured as a weighted average (weighted by area analyzed) of continuous tumor core average intensities (0–3) prior to 
dichotomization. Of 190 subjects, 2 had missing data for E-cadherin, but multiple imputation enabled retention of these 2 in Cox models
a
For effect of dichotomous E-cadherin expression (low versus high) on time-to-death, adjusted for age (continuous), TNM stage (local/regional/
distant), neoadjuvant chemotherapy (yes/no), and neoadjuvant radiation treatments (yes/no)
bStatistically-optimal cut point by best model fit
cUnadjusted comparisons of low versus high expression status
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